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Abstract
Although dietary, genetic, or disease-related excesses in urate
production may contribute to hyperuricemia, impaired renal
excretion of uric acid is the dominant cause of hyperuricemia in the
majority of patients with gout. The aims of this review are to
highlight exciting and clinically pertinent advances in our
understanding of how uric acid is reabsorbed by the kidney under
the regulation of urate transporter (URAT)1 and other recently
identified urate transporters; to discuss urate-lowering agents in
clinical development; and to summarize the limitations of currently
available antihyperuricemic drugs. The use of uricosuric drugs to
treat hyperuricemia in patients with gout is limited by prior
urolothiasis or renal dysfunction. For this reason, our discussion
focuses on the development of the novel xanthine oxidase inhibitor
febuxostat and modified recombinant uricase preparations.
Introduction
Gout is a crystal deposition disease with clinical manifesta-
tions that include acute gouty arthritis, chronic gouty
arthropathy, tophi, and renal functional impairment due to
monosodium urate (MSU) crystal deposition; and urolithiasis
and obstructive uropathy due to uric acid crystal deposition
[1]. Gout ultimately results from inflammatory and/or
degenerative responses to one or more derangements in the
metabolism or physiology of urate, the obligatory end-product
of human purine degradation [2]. In all untreated patients with
gout, the body pool of urate exceeds normal, the level of
serum urate is elevated, and the accompanying state of urate
supersaturation predisposes to clinical events [3]. Persistent
hyperuricemia (defined as a serum urate level >6.8 mg/dl)
reflects extracellular fluid supersaturation for urate; it is simple
to measure and is the primary risk factor for symptomatic
gout. Although dietary, genetic, or disease-related excesses
in urate production underlie hyperuricemia in some affected
individuals [3], impaired renal excretion of uric acid is the
dominant cause of hyperuricemia in the majority of patients
with gout [1-3].
Urate physiology
A weak organic acid with a pKa1 of 5.75, uric acid is the final
product of human purine metabolism. At the physiologic pH
of 7.4 in extracellular fluid, the concentration of urate ion is
approximately 50-fold that of the less soluble un-ionized uric
acid. Because of the high concentration of sodium in
extracellular fluid, urate is largely present as MSU; a
consequence of this is that the appreciable solubility of urate
ion (120 mg/dl at 37°C) is replaced by the much lower
solubility of MSU (approximately 6.8 mg/dl). As urate concen-
trations increasingly exceed 6.8 mg/dl, the risk for urate
crystal formation and precipitation increases. At pH 5.0 (often
found in urine), undissociated uric acid predominates, with a
solubility of approximately 10–15 mg/dl [3].
The human diet contains little urate. Urate is synthesized
endogenously in the liver and, to a lesser extent, in the small
intestine and circulates relatively free of protein binding
(<4%), so that all, or nearly all, urate is filtered at the
glomerulus before undergoing extensive net renal tubular
reabsorption (see below). Purine ingestion, endogenous
synthesis of purines from nonpurine precursors, and re-
utilization of preformed purine compounds are the sources of
urate production, an overall process that under steady state
conditions is balanced by uric acid disposal [4]. Daily renal
uric acid excretion is equivalent to about two-thirds of daily
production, and urate secretion into the small intestine, with
breakdown of urate by gut bacteria (intestinal uricolysis),
accounts for nearly all of the remainder of urate disposal [5].
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Humans and certain other primate species lack expression of
uricase [6], the enzyme that catalyzes conversion of urate to
allantoin, which is a substantially more soluble product than
urate and that is easily eliminated by renal excretion.
Consequently, serum urate levels are several fold higher in
normal humans than in rodents, for example. The body pool of
urate in humans is normally composed entirely of soluble
urate. In normal men and women the urate pools range from
about 800 to 1500 mg and from about 500 to 1000 mg,
respectively, with a daily turnover (the balanced production
and disposal of urate) of about 0.6–0.7 pools/day [3,4].
Imbalance between the production and disposal of urate may
result in expansion and supersaturation of the urate pool
[3,4], sometimes resulting in urate crystal deposition and,
ultimately, the formation of tophi, which may or may not be
measurable in estimates of the miscible urate pool [3].
In about 90% of individuals with sustained hyperuricemia,
impaired renal uric acid excretion is the dominant mechanism
underlying expansion of the urate pool [1-3]. Important
advances in our understanding of renal uric acid excretion are
discussed below. Xanthine oxidase, the enzyme that
catalyzes the terminal steps in urate production, namely
oxidation of the purine bases hypoxanthine to xanthine and
xanthine to uric acid, is a critical target of drug action in the
treatment of hyperuricemia; this is also discussed below.
Hyperuricemia may also be caused by excessive urate
production alone or in combination with impaired renal uric
acid excretion [1-3,7]. The pathways of purine metabolism
[3], their normal regulation [8,9], and regulatory aberrations
that lead to urate overproduction [2,3,8,9] are reviewed in
detail elsewhere.
Impaired renal uric acid excretion in gout
Most individuals with hyperuricemia and impaired renal uric
acid excretion have normal amounts of uric acid in their daily
urine. However, excretion of normal amounts of uric acid in
these individuals is accomplished only when serum urate
levels are, on average, 2–3 mg/dl higher than in normal
persons excreting comparable amounts of uric acid [10].
Renal hyperuricemia may be primary (idiopathic) and
unassociated with an identifiable disorder or drug regimen, or
it may be secondary to any of the broad array of disorders,
treatments, or toxic states that disrupt the mechanisms
involved in renal uric acid excretion [2]. Although some
patients with primary hyperuricemia and gout may have
impaired tubular urate secretory capacity [11], it seems
unlikely that there is a unitary mechanism for hyperuricemia
due to decreased renal uric acid excretion. In fact, the weight
of evidence supports the view that, as in secondary gout,
multiple renal processes for handling uric acid can be targets
for disruption in patients with primary hyperuricemia.
Despite nearly complete filtration of urate at the glomerulus,
uric acid clearance averages only 8–12% that of inulin or
creatinine, reflecting the net reabsorption of about 90% of
filtered urate. Over several decades, the multiple processes
that mediate proximal convoluted tubule handling of filtered
urate were operationally defined by studying the effects of
inherited mutations and pharmacologic agents on renal uric
acid excretion and by applying classic methods of renal
physiology [12].
A multicompartmental model for renal uric acid handling,
generated using the above approaches, included glomerular
filtration; proximal tubule (S1 segment) reabsorption of
virtually all filtered urate; secretion of 45–50% of reabsorbed
urate (S1 and S2 segments of the proximal tubule); and
postsecretory reabsorption of secreted urate (S3 segment of
the proximal tubule). Thus, net excretion of uric acid is
composed almost entirely of secreted rather than filtered
urate. This model did not achieve consensus [12], however;
in part this was because the compounds used to evaluate the
components were not entirely specific in their sites of action,
especially the use of drugs such as pyrazinamide and
probenecid. Fortunately, the application of newer
methodologies has begun to clarify the dynamics and
molecular bases of renal uric acid excretion.
Central role of URAT1 in renal urate
reabsorption and the target of uricosuric drugs
Recent molecular biological approaches have resulted in the
cloning of an organic anion transporter (OAT) family member
called urate transporter (URAT)1 (Fig. 1) [13]. URAT1 has
highly specific urate transport activity, exchanging this anion
with others including most of the endogenous organic anions
(e.g. lactate) and drug anions (e.g. the monocarboxylate
metabolite of pyrazinamide) that are known to affect renal uric
acid transport. URAT1 localizes selectively to the luminal
surface of the renal proximal tubular epithelial cell and
mediates a non-voltage-dependent exchange, with properties
compatible with a role for URAT1 as a major determinant of
urate reabsorption [13,14]. Interaction of URAT1 with the
PDZ domain-containing protein PDZK1 is essential for
URAT1 to maintain a conformation for the urate exchange
function [15]. Of clinical importance, URAT1-mediated urate
reabsorption in the proximal tubule is potently suppressed by
the uricosuric drugs probenecid, benzbromarone, sulfinpyra-
zone, and losartan [13] (Fig. 1).
That affected individuals in families with ‘loss of function’
mutations in the gene encoding URAT1 (SLC22A12)
demonstrate hypouricemia and hyperuricosuria as well as
functional renal impairment supports the suggestion that
URAT1 is the most potent regulator of serum urate levels
[13,14]. Additional studies support a role of URAT1 and
possibly other urate transport/exchange molecules in hyper-
uricemia and gout. A specific URAT1 gene sequence variant
is associated, when carried in the heterozygous state, with
less frequent gout and substantially lower serum uric acid
levels among Japanese individuals [16]. Pyrazinamide,
benzbromarone, and probenecid do not significantly affectPage 3 of 9
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urinary uric acid clearance in subjects with defective URAT1
transport function [14]. Finally, sex, sex hormones, aging,
diuretic therapy, and experimentally induced hyperuricemia (in
rats) have been observed to modulate the intrarenal
expression patterns of certain OAT family members [17-20].
For example, estrogen suppresses proximal tubule epithelial
cell OAT expression [17], a finding that may explain the
higher renal urate clearances, lower serum urate levels, and
much reduced incidence of gout in premenopausal women
as opposed to men and postmenopausal women.
UAT-1 and UMOD in renal uric acid disposition
A second candidate renal urate transporter, urate transporter/
channel 1 (UAT-1), mediates voltage-dependent urate channel-
ing in transfected cells and artificial membranes [21]. UAT-1
is more widely distributed in tissues than is URAT1, and it has
been identified as galectin-9, one of a family of proteins with a
number of nontransport functions including modulation of cell
adhesion and differentiation [21,22]. The role of UAT-1 in the
physiologic renal tubular transport or intestinal transport
(specifically secretion) of urate remains to be established
[13]. A number of other organic acid transporters and
additional candidate exchangers may also participate in urate
handling, particularly at the basolateral membrane of proximal
tubule epithelial cells [23-25].
Further insight into the mechanisms that affect renal uric acid
excretion has been provided by studies of familial juvenile
hyperuricemic nephropathy (FJHN), an autosomal dominantly
inherited disorder that is characterized by early onset of
hyperuricemia (with or without gout), hypertension, and
progressive renal failure culminating in end-stage renal
disease by age 40 years [26]. Severely impaired renal uric
acid clearance is present early, and the ensuing progressive
nephropathy does not appear to be dependent on urate/uric
acid crystal deposition [27]. Most affected families harbor a
mutation in the chromosome 16p-linked UMOD gene, usually
in a base that is involved in specifying a cysteine residue
[28,29]. This gene encodes uromodulin (the Tamm–Horsfall
glycoprotein), a disulfide bond-rich molecule that is normally
the most abundant protein in human urine [30]. Among
several mechanisms proposed to explain the relationship of
altered uromodulin expression and the FJHN phenotype [31]
is the hypothesis that uromodulin promotes maintenance of
the structural and functional integrity of the ascending limb of
the loop of Henle by providing a gel-like protective lattice.
Compromise of uromodulin structure and function is believed
to impair distal nephron sodium chloride reabsorption, with an
ensuing fluid volume depletion that activates voltage-
dependent sodium/urate cotransport at the proximal tubule.
Mutations in UMOD also characterize variant forms of
medullary cystic kidney disease (MCKD type 2) and glomerulo-
cystic kidney disease (GCKD) as well as FJHN [32], which
are thus allelic disorders with FJHN. These hyperuricemia-
associated disorders are characterized by tubulointerstitial
nephropathy and fibrosis, although glomerulocystic kidney
disease is also associated with dilation of Bowman’s space
and glomerular tuft collapse. The possibility that other more
subtle defects in uromodulin structure and expression may
also explain gout in additional patients is under investigation.
Current and future roles of uricosuric agents
in urate-lowering strategies
Uricosuric agents have long been used in the treatment of
hyperuricemia associated with gout [33]. Probenecid, the
only uricosuric agent currently used for this purpose in the
USA, remains useful in patients with primary gout who have
decreased renal uric acid excretion in the setting of well
preserved renal function (creatinine clearance ≥60 ml/min)
[1,34]. Unfortunately, all uricosuric agents currently available
in the USA are generally ineffective and potentially
nephrotoxic when used to treat hyperuricemia associated
with moderate chronic kidney disease (creatinine clearance
30–60 ml/min) [33,34]. Given the marked rise in prevalence
of both renal insufficiency and gout during the past 2 decades
[35], therapy for hyperuricemia in complicated gout is likely to
require approaches other than uricosuric drugs, such as safer
and more effective xanthine oxidase inhibitors or modified
recombinant uricase preparations.
Xanthine oxidase in the generation of uric acid
and as a drug target for urate-lowering agents
Degradation of purine nucleotides and nucleosides to purine
bases yields the key urate precursors hypoxanthine and
guanine (Fig. 2). Ordinarily, most of the hypoxanthine and
guanine produced is reutilized in a salvage reaction with 5-
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Figure 1
Urate anion transport function of URAT1 in renal proximal tubule
epithelial cells. Schematic representation of urate reabsorption in the
proximal tubule. Urate reabsorption at the apical (luminal) membrane is
critically regulated by URAT1. The organic anion transporter URAT1
exchanges tubular lumen urate with anions inside proximal tubular
epithelial cells. Potent stimulators of the exchange process include the
intracellular organic ions lactate, nicotinate, and the monocarboxylate
metabolite of the anti-tuberculous drug pyrazinimde. Certain
intracellular inorganic ions, including chloride, also stimulate urate
exchange by URAT1 but with lesser potency. As depicted, urate
reabsorption is suppressed at the luminal membrane by some drugs,
including benzbromarone, probenecid, losartan, and sulfinpyrazone,
consistent with their urisouric properties. Other agents. that affect
urate reabsorption in the proximal tubule, including furosemide and
salicylates, may act partly by regulating URAT1 function.phosphoribosyl 1-pyrophosphate (PRPP), which is catalyzed
by the enzyme hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT). The remaining guanine is deaminated to
xanthine, and unsalvaged hypoxanthine is oxidized to
xanthine, which undergoes further oxidation to uric acid. The
enzyme xanthine oxidase catalyzes both the conversion of
hypoxanthine to xanthine and xanthine to urate (Fig. 3).
Xanthine oxidase is a molybdenum-pterin and iron sulfide
cluster-containing flavoprotein that exists in two inter-
convertible forms: an oxidase form that utilizes oxygen to
convert hypoxanthine to xanthine and xanthine to urate, and a
nicotinamide adenine dinucleotide (NAD+)-utilizing dehydro-
genase form [36,37]. The catalytic events in purine base
oxidation involve binding of the purine base substrate to the
active site of the oxidase form, with reduction in the
molybdenum moiety (valence +6) to reduced molybdenum
(+4) by donation of electrons and oxidation of the substrate
by water. Electrons are then transferred to the iron-sulfide
cluster and then to the flavin center. Reoxidation of the flavin
moiety by oxygen is accompanied by release of the product
as well as generation of hydrogen peroxide (H2O2) and
superoxide (O2
–). Inhibition of xanthine oxidase activity is the
major action of the most commonly employed class of agents
used to lower urate levels in patients with gout.
Xanthine oxidase inhibitors
Agents that function through direct inhibition of xanthine
oxidase activity include allopurinol and oxypurinol, which are
hydroxypyrazolopyrimidine analogs of hypoxanthine and
xanthine, respectively; and febuxostat, which is a thiazole-
carboxylic acid derivative that is not a purine analog (Fig. 4).
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Figure 3
Reactions catalyzed by xanthine oxidase (also known as xanthine
oxidoreductase). The enzyme exists in dehydrogenase and oxidase
forms, accepting NAD+ in the former conformation and O2 in the latter.
Reversible interconversion of the forms involves disulfide bond
formation and disruption.
Figure 4
Comparison of structures of allopurinol, oxypurinol, and febuxostat.
Clinically utilized xanthine oxidase inhibitors. Allopurinol and its
oxidation product oxypurinol are hydroxypyrazolopyrimidine analogues,
respectively, of hypoxanthine and xanthine. As such, each can affect
the activities of enzymes of purine and pyrimidine metabolism other
than xanthine oxidase. Febuxostat is a thiazolecarboxylic acid derivative
that does not resemble a purine or pyrimidine and has shown
substantial specificity as a xanthine oxidase inhibitor [50].
Figure 2
Xanthine oxidase in the context of purine metabolism. Schematic
representation of human purine metabolic pathways, culminating in the
production of uric acid. Purine nucleotides are synthesized by
alternative pathways, each requiring the key regulatory intermediate
5-phosphoribosyl 1-pyrophosphate (PRPP), which is synthesized from
ATP and ribose-5-P in a reaction catalyzed by PRPP synthetase. The
pathway of purine synthesis de novo involves a sequence of 10
reactions by means of which a purine ring is synthesized on a ribose-
phosphate backbone donated by PRPP. The first reaction in the
pathway is the rate-limiting step and is catalyzed by the enzyme
amidophopshoribosyltransferase (AmidoPRT). The subsequent 9
reactions in the de novo pathway are represented by the dashed
arrow. The alternative pathways of purine nucleotide synthesis are
single step processes by which preformed purine bases (adenine,
Ade; hypoxanthine (Hyp); guanine, Gua) are salvaged in reactions
catalyzed by the phosphoribosyltransferase (PRT) enzymes
adeninePRT (APRT) and hypoxanthine-guanine (HPRT), respectively.
Regulation of nucleotide synthesis is effected mainly at the AmidoPRT
step, by means of antagonistic allosteric regulation of the activity of
AmidoPRT by inhibitory (–) purine nucleotide products and PRPP
activation. Purine nucleotide products also inhibit PRPP synthetase
activity. Purine nucleotides and nucleosides are readily interconverted
by means of an extensive and complex series of enzyme-catalyzed
reactions that provide the cellular requirements for balanced availability
of adenine and guanine nucleotides and nucleosides. Phosphorolysis
of the nucleosides inosine and guanosine result in production of Hyp
and Gua, which are either salvaged (in the HPRT reaction) or are
ultimately and irreversibly oxidized through the base xanthine (Xan) to
the end product, uric acid, in reactions catalyzed by xanthine oxidase.Allopurinol
Allopurinol is the most commonly used antihyperuricemic
agent and is the only xanthine oxidase inhibitor approved to
date by the US Food and Drug Administration. This drug
inhibits xanthine oxidase by a competitive mechanism with
respect to the natural purine base substrates [3,37,38].
Allopurinol binds to the oxidized form of xanthine oxidase at
the active site Mo6+-pterin coenzyme, and, in the process of
reducing it, generates the oxidized form of allopurinol, namely
oxypurinol. Advantages of allopurinol are a once-daily dosing
regimen and urate-lowering efficacy regardless of the cause
of hyperuricemia.
Few studies comparing the relative efficacy of xanthine
oxidase inhibitors and uricosuric agents have been reported.
In one prospective study [39], drug efficacy in reducing
serum urate concentrations in primary chronic gout was
tested in 86 male patients. Of these, 49 patients (including
26 who excreted normal amounts of urinary uric acid daily
and 23 with under-excretion) received allopurinol
300 mg/day. A total of 37 under-excretors received benzbro-
marone (a potent uricosuric drug) at 100 mg/day. Treatment
was adjusted to achieve plasma urate concentrations under
6.0 mg/dl. Among patients who received allopurinol, mean
plasma urate reductions of 2.75 mg/dl and 3.34 mg/dl were
achieved in normal excretors and under-excretors, respect-
ively; a mean reduction of 5.04 mg/dl was observed among
those who received benzbromarone (Fig. 5). Only 53% of
patients receiving allopurinol at the commonly used dose of
300 mg/day achieved the target urate level as compared with
100% of benzbromarone-treated patients. Increasing the allo-
purinol dose improved the urate-lowering efficacy achieved
with this drug.
Major limitations of allopurinol are summarized in Table 1. The
most common undesired effect of xanthine oxidase inhibition
is precipitation of acute attacks of gout, particularly among
patients in whom colchicine or nonsteroidal anti-inflammatory
drug prophylaxis is not utilized. Because sudden increases or
decreases in serum urate concentration can trigger acute
gouty attacks, xanthine oxidase inhibitor therapy is generally
not initiated during an acute attack of gout. A major side
effect of allopurinol is hypersensitivity. Rash develops in
about 2% of patients receiving allopurinol and is generally
reversible on discontinuation of the drug [40]. Severe
allopurinol hypersensitivity [41], which can include not only
exfoliative dermatitis but also vasculitis and multiorgan system
failure, occurs in under 1/1000 patients and is more likely to
occur in patients with renal disease or those receiving
thiazide diuretics and standard doses of allopurinol. In Han
Chinese, severe allopurinol cutaneous reactions were
recently linked to the HLA-B*5801 haplotype [42], a finding
that has not yet been confirmed in other populations. Current
urate-lowering options in allopurinol-hypersensitive gout
patients who have had mild-to-moderate but not severe
adverse reactions and who are not candidates for uricosuric
therapy include: oral allopurinol desensitization, which is
efficacious in about 50% of subjects [43]; and the use of
oxypurinol (the active metabolite of allopurinol; described
below). Cross-sensitivity of allopurinol and oxypurinol limits
effective use of oxypurinol in allopurinol-hypersensitive patients.
Other allopurinol side effects, including hepatic toxicity with
serum transaminase elevation, render approximately 10% of
treated persons unable to tolerate this agent. Furthermore, for
patients with chronic kidney disease [40] the prolonged half-
life of renal elimination of oxypurinol limits the recommended
maximum allopurinol dosage because of concerns about an
increased incidence of hypersensitivity reactions. A major
issue currently limiting effective allopurinol use is patient
compliance. In one study [44], for example, compliance with
allopurinol over 2 years of treatment was only about 20%. It
seems likely that insufficient patient education regarding the
long-term aims of urate-lowering therapy contributes to this
problem, which is shared by therapies for other treatable
disorders that may be asymptomatic for substantial periods of
time.
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Figure 5
Comparative effects of allopurinol and benzbromarone on plasma urate
levels. Initial and final plasma urate (Pur) after standard doses of urate-
lowering drugs allopurinol (300 mg/day) or benzbromarone
(100 mg/day). *For final versus initial plasma urate, P < 0.01 for
allopurinol groups and P < 0.001 for benzbromarone group. Adapted
from [39]. Copyright 1998 with permission from BMJ Publishing Group.
Table 1
Major limitations of allopurinol therapy
Rash in about 2% of treated patients
Additional intolerance in up to 10% of patients (includes hepatic
enzyme, gastrointestinal, and central nervous system effects)
Allopurinol hypersensitivity syndrome: <1/1000 treated patients, but
20% fatality rate
Prolonged renal elimination of active oxypurinol metabolite
necessitates reduced dose in renal disease with impaired function
Contraindicated in patients receiving azathioprine or 6-mercaptopurineOxypurinol
Oxypurinol [45] is currently only available on a compassion-
ate-use basis in the USA and Canada, and may be useful and
effective in most (but not all) patients with mild-to-moderate
allopurinol intolerance.
Like allopurinol, oxypurinol is a competitive inhibitor of xanthine
oxidase. In contrast to allopurinol, oxypurinol binds to the
reduced form of the enzyme with very high affinity but is
released from xanthine oxidase when the enzyme is
reoxidized. Oral absorption of oxypurinol is poor relative to
allopurinol, and oxypurinol doses may require extended
titration to achieve satisfactory lowering of serum urate.
Febuxostat
Febuxostat is an orally administered selective inhibitor of
xanthine oxidase that is not a purine analog. The mechanism
of febuxostat inhibition of the enzyme is mixed inhibition,
contrasting with the competitive kinetics exhibited by
allopurinol. This difference in kinetic mechanism is consistent
with the findings that febuxostat blocks substrate access to
the molybdenum-pterin moiety of xanthine oxidase by occupy-
ing a channel in the enzyme leading to the active site (Fig. 6),
and that febuxostat inhibits both the oxidized and reduced
forms of xanthine oxidase [46,47]. In animal studies [47-49]
febuxostat was shown to provide more potent and longer
lasting hypouricemic activity than allopurinol, and has minimal
effects on other enzymes that are involved in purine and
pyrimidine metabolism (Fig. 7) [50]. Unlike currently available
xanthine oxidase inhibitors, febuxostat is metabolized primarily
by hepatic glucuronide formation and oxidation and is
excreted in about equal proportions in stool and urine [51].
The efficacy of febuxostat was examined in a phase II study
[52] in which 153 patients with gout and hyperuricemia
(baseline serum urate levels ≥8.0 mg/dl) were randomly
assigned to therapy with febuxostat (40, 80, or 120 mg/day)
or to placebo once daily for 28 days. Patients received
colchicine prophylaxis during a 2-week washout period and
for the first 2 weeks of double-blind treatment. The primary
end-point was the percentage of patients with serum urate
levels below 6.0 mg/dl after 28 days of therapy. The primary
end-point was achieved in 0% of patients in the placebo
group and, in a dose-related manner, in between 56% and
94% of patients in the febuxostat-treated groups. Mean
serum urate reduction from baseline was 2% in the placebo
group; among patients in the febuxostat groups the
reductions ranged from 37% in the 40 mg/day group to 59%
Arthritis Research & Therapy    Vol 8 Suppl 1 Terkeltaub et al.
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Figure 6
Febuxostat blockade of substrate access to the active site of both
reduced and oxidized xanthine oxidase. Space-taking representation of
the interaction of febuxostat and amino acid residues of xanthine
oxidase. Febuxostat, represented in green, occupies the channel
accessing the Mo-pterin moiety in the active site of xanthine oxidase. In
contrast to allopurinol and oxypurinol, which bind directly to the active
site and result in competitive inhibition of enzyme activity, febuxostat
blocks substrate access to the channel resulting in a pattern of mixed
inhibition of enzyme activity. Reprinted with permission from [46]. 
© 2006 American Society for Biochemistry and Molecular Biology.
Figure 7
Multiple sites of allopurinol action on pathways of purine and pyrimidine metabolism. Reactions inhibited by allopurinol are shown in red; reactions
unaffected are shown in green. Allopurinol or its metabolites also result in depletion of intracellular 5-phosphoribosyl 1-pyrophosphate (PRPP)
concentrations. AMP, adenosine monophosphate; CTP, cytosine triphosphate; GMP, guanosine monophosphate; HGPRT, hypoxanthine-guanine
phosphoribosyltransferase; IMP, inosine monophosphate; OMPDC, orotidine-5′-monophosphate decarboxylase; OMP, orotidine monophosphate;
OPRT, orotate phosphoribosyltransferase; PNP  purine nucleoside phosphorylase; PRPP, 5-phosphoribosyl 1-pyrophosphate; UMP, uridine
monophosphate; UTP, uridine triphosphate; XOD, xanthine oxidase.in the 120 mg/day group. The incidence of treatment-related
adverse events was similar in the placebo and 40 mg/day
febuxostat groups. Gout flares occurred in a similar
percentage of patients in the febuxostat 40 mg/day and
placebo groups (37% and 35%, respectively), with higher
frequency among patients who received the 80 mg/day dose
(43%) and 120 mg/day dose (55%) of febuxostat. The
proportions of patients in the intent-to-treat population who
achieved the primary end-point are shown in Fig. 8.
In a recently reported 1-year phase III randomized controlled
trial comparing 80 mg/day and 120 mg/day doses of
febuxostat with allopurinol at 300 mg/day in patients with gout
and serum urate levels of 8.0 mg/dl or greater [53], both
doses of febuxostat resulted in sustained and superior (to
allopurinol) urate-lowering efficacy. Nevertheless, after 1 year
of treatment, the secondary outcomes of reduction in gout
flares and tophus area were not different in the febuxostat and
allopurinol group, and the overall incidence of treatment-
related adverse events-most of which were mild and moderate
in severity- was similar for all treatment groups. However, a
significantly greater number of patients in the febuxostat
120/day group discontinued therapy (P = 0.003).
Uricase
The importance of the hepatic enzyme uricase in urate
balance has been underlined by the marked hyperuricemia
and renal tubulopathy induced by engineered uricase gene
inactivation in the mouse. Serum urate levels in uricase
knockout mice are about 10-fold higher than in wild-type mice
(1 mg/dl) [54]. Recombinant Aspergillus flavus uricase
(Rasburicase™; Sanofi-Synthelabo, Malvern, PA, USA),
administered in a single short-term course, is US Food and
Drug Administration approved for prevention of tumor lysis
syndrome [55]. Recombinant uricase therapy profoundly
lowers serum urate levels. Unlike currently available urate-
lowering therapies, uricase can promote accelerated tophus
dissolution in a therapeutic course limited to 3 months in
duration [56]. However, unmodified uricase is highly
immunogenic and can trigger severe and potentially lethal
side effects (e.g. anaphylaxis) [57-59]. Moreover, hydrogen
peroxide, a product of the uricase reaction (Fig. 9), stimulates
cell transformation in vitro [60], raising concern with respect
to long-term therapy with uricase. Uricase-induced redox
stress can trigger hemolysis and methemoglobinemia in
patients with glucose-6-phosphate dehydrogenase (G6PD)
deficiency [57-59], precluding uricase treatment of patients
with this disorder. This also prompts the question of whether
concurrently clearing the serum of the major circulating
antioxidant (urate) and generating hydrogen peroxide without
providing for alternative antioxidants will compromise the
unstable lesions (e.g. arteriosclerotic plaques or other sites of
chronic redox stress) in which urate can accumulate [61,62].
Neutralizing antibodies frequently develop in the course of
treatment with purified native or unmodified recombinant
uricase [55,57-59]. In order to reduce antigenicity and
prolong the half-life of uricase activity, polyethyleneglycol
modified forms of recombinant uricase have been developed,
and two such biologic agents are currently in clinical trials
[63,64]. It is likely that the therapeutic niches for modified
uricases in the treatment of gout will be for short-term
acceleration of tophus dissolution (‘debulking’) in carefully
selected patients with large tophus burdens and perhaps for
more long-term use in patients intolerant of or unresponsive
to all other forms of urate-lowering therapy.
Conclusion
Gout is among the oldest recognized rheumatic diseases.
Current research into the physiologic mechanisms and
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Figure 8
Serum urate-lowering efficacy of febuxostat compared with placebo.
Subjects with gout and baseline serum urate levels >8.0 mg/dl
received once daily doses of placebo or febuxostat for 28 days.
Modified from [52].
Figure 9
Action of uricase to catabolize uric acid to allantoin. Uricase (urate
oxidase) gene expression and the depicted uricase reaction are lacking
in humans, as discussed in the text. PEGylated recombinant uricase
preparations are now under investigation for treatment of refractory
hyperuricemia in gout, and have the potential to rapidly reduce
(“de-bulk”) tophus burden.molecular processes that underlie hyperuricemia and gout
has identified a range of targets for pharmacotherapy and is
fostering the development of new drugs and biologic agents
for reversing hyperuricemia. The future promises more
effective treatments for patients with difficult-to-manage gout,
including those with renal insufficiency, allopurinol intolerance,
and extensive tophi.
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